Skip to main content

Table 3 Case series data of the number of total/laryngeal HAE attacks in the year prior to initiating lanadelumab compared to the year following initiation of lanadelumab

From: Impact of lanadelumab in hereditary angioedema: a case series of 12 patients in Canada

Case Pre-lanadelumab transition Post-lanadelumab transition
Attacks/year Laryngeal attacks/year Treated attacks/year Missed work days/year ISO Attacks /year Laryngeal attacks/year Treated attacks/year Missed work days/year ISO
1 10 4 6 6 2 2 0 2 0 1
2 12 0 6 20 2 4 0 0 0 1
3 8 2 8 0 4 2 1 2 0 2
4 6 0 6 0 3 0 0 0 0 1
5 50 0 25 0 5 20 0 20 0 2
6 300 50 50 Offa 5 100 40 40 Offa 1
7 15 0 0 Offb 4 12 0 0 Offb 1
8 6 0 6 0 3 2 0 2 0 2
9 10 0 6 0 2 0 0 0 0 1
10 30 0 12 Retired 3 6 0 6 Retired 1
11 12 0 12 Off3 2 6 0 6 Offc 1
12 3 0 3 Off4 3 0 0 0 Offd 3
  1. Treated attacks are the number of times an acute attack was treated with breakthrough therapy. ISO was determined from MD review of patient clinical encounter notes pre- and post-lanadelumab. ISO, impact on social outings (1 = no impact, 3 = some, 5 = a lot)
  2. aThis patient is unable to work due to the frequency of her attacks
  3. bThis patient is a homemaker and is not employed
  4. cThis patient is off work due to a prior motor vehicle accident in 1999 causing cervical stenosis and progressive myelopathy
  5. dThis patient is off work due to chronic comorbid medical conditions (T1DM, Adrenal Insufficiency)